The US Food & Drug Administration is once more considering the possibility of making opioid prescriber education mandatory as a condition of the class wide Risk Evaluation & Mitigation Strategy for the analgesic class – and it may be difficult to back down yet again from taking a step that stakeholders continue to see as unduly burdensome and even counterproductive.
Speakers at last month’s FDA/Duke-Margolis meeting on “revisiting” mandatory prescriber education for opioids agreed that changes are needed to the...